Good gene, bad gene: New APP variant may be both

Progress in Neurobiology

Volumn 99, Issue 3, 2012, Pages 281-292

  Di Fede, Giuseppe ^a   Catania, Marcella ^a   Morbin, Michela ^a   Giaccone, Giorgio ^a   Moro, Maria Luisa ^a   Ghidoni, Roberta ^b   Colombo, Laura ^c   Messa, Massimo ^c   Cagnotto, Alfredo ^c   Romeo, Margherita ^c   Stravalaci, Matteo ^c   Diomede, Luisa ^c   Gobbi, Marco ^c   Salmona, Mario ^c   Tagliavini, Fabrizio ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

A2V A ; A673V APP mutation; Alzheimer's disease; Amyloid; Amyloid (A ); Amyloid precursor protein (APP); APP mutation; Recessive mutation; Therapy

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ATOMIC FORCE MICROSCOPY; AUTOSOMAL RECESSIVE INHERITANCE; COGNITIVE DEFECT; ELECTRON MICROSCOPY; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INCUBATION TIME; NEUROPATHOLOGY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MUTATION; PEPTIDE FRAGMENTS;

EID: 84869878607     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.06.004     Document Type: Review

References (68)

1. Albertini V., Bruno A., Paterlini A., Lista S., Benussi L., Cereda C., Binetti G., Ghidoni R. Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics - Clinical Applications 2010, 4:352-357.
2. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2023-2028.
3. Bieler S., Soto C. Beta-sheet breakers for Alzheimer's disease therapy. Current Drug Targets 2004, 5:553-558.
4. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
5. Bugiani O., Giaccone G., Rossi G., Mangieri M., Capobianco R., Morbin M., Mazzoleni G., Cupidi C., Marcon G., Giovagnoli A., Bizzi A., Di Fede G., Puoti G., Carella F., Salmaggi A., Romorini A., Patruno G.M., Magoni M., Padovani A., Tagliavini F. Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Archives of Neurology 2010, 67:987-995.
6. Bush A.I., Tanzi R.E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008, 5:421-432.
7. Cai X.-D., Golde T.E., Younkin S.G. Release of excess amyloid β-protein from a mutant amyloid β-protein precursor. Science 1993, 259:514.
8. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992, 360:672-674.
9. Di Fede G., Catania M., Morbin M., Rossi G., Suardi S., Mazzoleni G., Merlin M., Giovagnoli A.R., Prioni S., Erbetta A., Falcone C., Gobbi M., Colombo L., Bastone A., Beeg M., Manzoni C., Francescucci B., Spagnoli A., Cantù L., Del Favero E., Levy E., Salmona M., Tagliavini F. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
10. 2+ coordination. PLoS One 2010, 5:e15875.
11. Ewald C.Y., Li C. Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system. Brain Structure and Function 2010, 214:263-283.
12. Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiology of Aging 2002, 23:1009-1016.
13. Ghidoni R., Albertini V., Squitti R., Paterlini A., Bruno A., Bernardini S., Cassetta E., Rossini P.M., Squitieri F., Benussi L., Binetti G. Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. Journal of Alzheimer's Disease 2009, 18:295-303.
14. Ghidoni R., Paterlini A., Albertini V., Stoppani E., Binetti G., Fuxe K., Benussi L., Agnati L.F. A window into the heterogeneity of human cerebrospinal fluid Aβ peptides. Journal of Biomedicine and Biotechnology 2011, 2011:697036.
15. Giaccone G., Morbin M., Moda F., Botta M., Mazzoleni G., Uggetti A., Catania M., Moro M.L., Redaelli V., Spagnoli A., Rossi R.S., Salmona M., Di Fede G., Tagliavini F. Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathologica 2010, 120:803-812.
16. Glabe C.G. Structural classification of toxic amyloid oligomers. Journal of Biological Chemistry 2008, 283:29639-29643.
17. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
18. Härtig W., Goldhammer S., Bauer U., Wegner F., Wirths O., Bayer T.A., Grosche J. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. Journal of Chemical Neuroanatomy 2010, 40:82-92.
19. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. Journal of Molecular Biology 1992, 228:460-473.
20. Holtzman D.M., Goate A., Kelly J., Sperling R. Mapping the road forward in Alzheimer's disease. Science Translational Medicine 2011, 3:114ps48.
21. Hori Y., Hashimoto T., Wakutani Y., Urakami K., Nakashima K., Condron M.M., Tsubuki S., Saido T.C., Teplow D.B., Iwatsubo T. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Abeta fibril formation without increasing protofibril formation. Journal of Biological Chemistry 2007, 282:4916-4923.
22. Huang H.C., Jiang Z.F. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. Journal of Alzheimer's Disease 2009, 16:15-27.
23. Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:5819-5824.
24. Kaminsky Y.G., Marlatt M.W., Smith M.A., Kosenko E.A. Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Experimental Neurology 2010, 221:26-37.
25. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews Drug Discovery 2011, 10:698-712.
26. Kuroyanagi H., Kobayashi T., Mitani S., Hagiwara M. Transgenic alternative-splicing reporters reveal tissue-specific expression profiles and regulation mechanisms in vivo. Nature Methods 2006, 3:909-915.
27. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:6448-6453.
28. Larner A.J., Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. Journal of Neurology 2006, 253:139-158.
29. Lee E.B., Skovronsky D.M., Abtahian F., Doms R.W., Lee V.M. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. Journal of Biological Chemistry 2003, 278:4458-4466.
30. Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D., Lieberburg I., van Duinen S.G., Bots G.T., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage. Dutch type. Science 1990, 248:1124-1126.
31. Lim K.H. A weakly clustered N terminus inhibits Abeta(1-40) amyloidogenesis. Chembiochem 2006, 7:1662-1666.
32. Ling Y., Morgan K., Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. International Journal of Biochemistry and Cell Biology 2003, 35:1505-1535.
33. Link C.D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:9368-9372.
34. Lippa C.F., Swearer M., Kane K.J., Nochlin D., Bird T.D., Ghetti B., Nee L.E., St George-Hyslop P., Pollen D.A., Drachman D.A. Familial Alzheimer's disease: site of mutation influences clinical phenotype. Annals of Neurology 2000, 48:376-379.
35. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. Journal of the Neurological Sciences 1998, 158:47-52.
36. Mahoney T.R., Luo S., Nonet M.L. Analysis of synaptic transmission in Caenorhabditis elegans using an aldicarb-sensitivity assay. Nature Protocols 2006, 1:1772-1777.
37. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
38. McDonald J.M., Savva G.M., Brayne C., Welzel A.T., Forster G., Shankar G.M., Selkoe D.J., Ince P.G., Walsh D.M. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010, 133:1328-1341. Medical Research Council Cognitive Function and Ageing Study.
39. Meinhardt J., Tartaglia G.G., Pawar A., Christopeit T., Hortschansky P., Schroeckh V., Dobson C.M., Vendruscolo M., Fändrich M. Similarities in the thermodynamics and kinetics of aggregation of disease-related Abeta(1-40) peptides. Protein Science 2007, 16:1214-1222.
40. Nelson P.T., Kukull W.A., Frosch M.P. Thinking outside the box: Alzheimer-type neuropathology that does not map directly onto current consensus recommendations. Journal of Neuropathology and Experimental Neurology 2010, 69:449-454.
41. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., Näslund J., Lannfelt L. The " Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nature Neuroscience 2001, 4:887-893.
42. Nussbaum R.L., Ellis C.E. Alzheimer's disease and Parkinson's disease. New England Journal of Medicine 2003, 348:1356-1364.
43. Obici L., Demarchi A., de Rosa G., Bellotti V., Marciano S., Donadei S., Arbustini E., Palladini G., Diegoli M., Genovese E., Ferrari G., Coverlizza S., Merlini G. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Annals of Neurology 2005, 58:639-644.
44. Opazo C., Huang X., Cherny R.A., Moir R.D., Roher A.E., White A.R., Cappai R., Masters C.L., Tanzi R.E., Inestrosa N.C., Bush A.I. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). Journal of Biological Chemistry 2002, 277:40302-40308.
45. Peacock M.L., Warren J.T., Roses A.D., Fink J.K. Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer's disease. Neurology 1993, 43:1254-1256.
46. Querfurth H.W., LaFerla F.M. Alzheimer's disease. New England Journal of Medicine 2010, 362:329-344.
47. Rocchi A., Pellegrini S., Siciliano G., Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Research Bulletin 2003, 61:1-24.
48. Rossi G., Giaccone G., Maletta R., Morbin M., Capobianco R., Mangieri M., Giovagnoli A.R., Bizzi A., Tomaino C., Perri M., Di Natale M., Tagliavini F., Bugiani O., Bruni A.C. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology 2004, 63:910-912.
49. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerrière A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature Genetics 2006, 38:24-26.
50. Scheidt H.A., Morgado I., Rothemund S., Huster D. Dynamics of amyloid β fibrils revealed by solid-state NMR. Journal of Biological Chemistry 2012, 287:2017-2021.
51. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews 2001, 81:741-766.
52. Selkoe D.J. Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease. Journal of Clinical Investigation 2002, 110:1375-1381.
53. Soto C., Estrada L. Amyloid inhibitors and beta-sheet breakers. Subcellular Biochemistry 2005, 38:351-364.
54. Steinerman J.R., Irizarry M., Scarmeas N., Raju S., Brandt J., Albert M., Blacker D., Hyman B., Stern Y. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Archives of Neurology 2008, 65:906-912.
55. St George-Hyslop P.H. Piecing together Alzheimer's. Scientific American 2000, 283:76-83.
56. St George-Hyslop P.H. Molecular genetics of Alzheimer's disease. Biological Psychiatry 2000, 47:183-199.
57. St George-Hyslop P.H., Petit A. Molecular biology and genetics of Alzheimer's disease. Comptes Rendus Biologies 2005, 328:119-130.
58. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L., Eckman C., Golde T.E., Younkin S.G. An increased percentage of long amyloid-beta protein secreted by familial amyloid-beta protein precursor (APP717) mutants. Science 1994, 264:1336-1340.
59. Tagliavini F., Giaccone G., Frangione B., Bugiani O. Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neuroscience Letters 1988, 93:191-196.
60. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
61. Tsvetkov P.O., Popov I.A., Nikolaev E.N., Archakov A.I., Makarov A.A., Kozin S.A. Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer's disease amyloid beta(1-16) peptide. Chembiochem 2008, 9:1564-1567.
62. van Duinen S.G., Castaño E.M., Prelli F., Bots G.T., Luyendijk W., Frangione B. Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:5991-5994.
63. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
64. Williams A.D., Portelius E., Kheterpal I., Guo J.T., Cook K.D., Xu Y., Wetzel R. Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. Journal of Molecular Biology 2004, 335:833-842.
65. Wilquet V., De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Current Opinion in Neurobiology 2004, 14:582-588.
66. Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., Schmidt B., Klafki H.W., Maler M., Dyrks T., Bienert M., Beyermann M., Rüther E., Kornhuber J. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. Journal of Neurochemistry 2002, 81:481-496.
67. Wolfe M.S., Guénette S.Y. APP at a glance. Journal of Cell Science 2007, 120:3157-3161.
68. Wurth C., Guimard N.K., Hecht M.H. Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis. Journal of Molecular Biology 2002, 319:1279-1290.